Acta Neuropathologica

, Volume 125, Issue 5, pp 621-636

First online:

What do we know about IDH1/2 mutations so far, and how do we use it?

  • Craig HorbinskiAffiliated withDepartment of Pathology, University of Kentucky Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Whole genome analyses have facilitated the discovery of clinically relevant genetic alterations in a variety of diseases, most notably cancer. A prominent example of this was the discovery of mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) in a sizeable proportion of gliomas and some other neoplasms. Herein the normal functions of these enzymes, how the mutations alter their catalytic properties, the effects of their d-2-hydroxyglutarate metabolite, technical considerations in diagnostic neuropathology, implications about prognosis and therapeutic considerations, and practical applications and controversies regarding IDH1/2 mutation testing are discussed.


IDH1/2 2-Hydroxyglutarate Glioma Histone Methylation